Lack of Weight-Based Dose Dependency and Intraindividual Variability of Omeprazole for CYP2C19 Phenotyping

This publication has 22 references indexed in Scilit:

• Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker
  Clinical Pharmacology & Therapeutics, 2002
• Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N -acetyltransferase-2, and xanthine oxidase with the ″Cooperstown cocktail”
  Clinical Pharmacology & Therapeutics, 2000
• Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype*
  Clinical Pharmacology & Therapeutics, 1996
• Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects*
  Clinical Pharmacology & Therapeutics, 1996
• [23] Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism
  Published by Elsevier ,1996
• [14] Assays of omeprazole metabolism as a substrate probe for human CYP isoforms
  Published by Elsevier ,1996
• Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
  Pharmacogenetics, 1995
• The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*
  Clinical Pharmacology & Therapeutics, 1995
• Slow Omeprazole Metabolizers Are Also Poor S-Mephenytoin Hydroxylators
  Therapeutic Drug Monitoring, 1990
• Determination of omeprazole and metabolites in plasma and urine by liquid chromatography
  Journal of Chromatography B: Biomedical Sciences and Applications, 1983